An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability
- 1 April 2017
- journal article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 106 (4) , 1008-1017
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Optimizing Therapeutic Antibody FunctionBioDrugs, 2011
- Optimization of Fc-mediated effector functions of monoclonal antibodiesCurrent Opinion in Biotechnology, 2009
- Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 AntibodiesImmunological Investigations, 2009
- Intravenous immunoglobulins induce CD32-mediated platelet aggregationin vitroBritish Journal of Dermatology, 2008
- Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional PolymorphismClinical Cancer Research, 2004
- High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγRJournal of Biological Chemistry, 2001
- Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 FcThe Journal of Immunology, 2000
- Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cellsMolecular Immunology, 1997
- The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive propertiesEuropean Journal of Immunology, 1993
- A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibodyMolecular Immunology, 1993